J Michael Hamilton
Overview
Explore the profile of J Michael Hamilton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rahma O, Hamilton J, Wojtowicz M, Dakheel O, Bernstein S, Liewehr D, et al.
J Transl Med
. 2014 Feb;
12:55.
PMID: 24565030
Background: Mutant Ras oncogenes produce proteins that are unique to cancer cells and represent attractive targets for vaccine therapy. We have shown previously that vaccinating cancer patients with mutant ras...
2.
Hamilton J, Harding M, Genna T, Bol D
J Clin Pharmacol
. 2008 Oct;
49(1):30-8.
PMID: 18971325
A phase I study of AVN944, an inosine monophosphate dehydrogenase (IMPDH) inhibitor, was carried out to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics. Healthy male volunteers (N = 25) participated...
3.
Page L, Psaila B, Provan D, Hamilton J, Jenkins J, Elish A, et al.
Br J Haematol
. 2007 Jun;
138(2):245-8.
PMID: 17542983
A method for objective quantification of bleeding symptoms in immune thrombocytopenic purpura (ITP) has not been established. The ITP Bleeding Scale (IBLS) is a novel bleeding assessment system comprising 11...
4.
Grem J, Morrison G, Guo X, Agnew E, Takimoto C, Thomas R, et al.
J Clin Oncol
. 2005 Mar;
23(9):1885-93.
PMID: 15774780
Purpose: To determine the clinical toxicities of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) given as a 1-hour infusion daily for 5 days every 3 weeks. Patients And Methods: Nineteen patients received 17-AAG over six...
5.
Grem J, Quinn M, Keith B, Monahan B, Hamilton J, Xu Y, et al.
Cancer Chemother Pharmacol
. 2003 Sep;
52(6):487-96.
PMID: 12955469
Purpose: Since preclinical studies have shown more than additive cytotoxicity and DNA damage with the combination of gemcitabine and 5-fluoro-2'-deoxyuridine (FUDR), we studied this combination in a phase I trial....
6.
Guo X, Harold N, Saif M, Schuler B, Szabo E, Hamilton J, et al.
Cancer Chemother Pharmacol
. 2003 Apr;
52(1):79-85.
PMID: 12707718
Purpose: To determine the toxicities and pharmacokinetic effects of eniluracil (EU) given on two weekly dosing schedules with 5-fluorouracil (5-FU) and leucovorin (LV). Methods: A group of 26 patients received...
7.
Gulley J, Chen A, Dahut W, Arlen P, Bastian A, Steinberg S, et al.
Prostate
. 2002 Sep;
53(2):109-17.
PMID: 12242725
Background: A Phase I trial of recombinant vaccinia prostate specific antigen (rV-PSA) in patients with advanced metastatic prostate cancer was conducted. This report describes 42 patients who were treated with...
8.
Grem J, Harold N, Keith B, Chen A, Kao V, Takimoto C, et al.
Clin Cancer Res
. 2002 Jul;
8(7):2149-56.
PMID: 12114415
Purpose: Pyrazoloacridine (PZA) is an investigational nucleic acid binding agent that inhibits the activity of topoisomerases I and II through a mechanism distinct from other topoisomerase poisons. PZA shows schedule-independent...